Neuroendocrine profile of the potential anxiolytic drug S-20499

Andrew D. Levy, Qian Li, Michael Gustafson, Louis D. Van de Kar

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The neuroendocrine profile of the serotonin 5-HT1A receptor agonist and potential anxiolytic drug (+)-4[N-(5-methoxy-chroman-3-yl]N-propylamino]butyl-8-azaspiro-(4, 5)-decane-7,9-dione (S-20499) was examined in conscious male rats. S-20499 (0.01-20 mg/kg i.p.) dose-dependently elevated plasma adrenocorticotropin (ACTH) and corticosterone concentrations, with maximal effects observed at 15-30 and 30-60 min respectively. S-20499 also reduced plasma prolactin concentration, and did not alter plasma renin activity. S-20499 (1 mg/kg i.p.) also reduced blood pressure and heart rate within 10 min, suggesting reduced sympathetic output. Pretreatment with the 5-HT1A0 receptor antagonists (-)-pindolol (0.3 mg/kg i.p.) or spiperone (0.01 or 3 mg/kg s.c.) significantly attenuated the stimulatory effects of S-20499 on plasma ACTH and/or corticosterone concentrations. The data suggest that S-20499 stimulates the hypothalamic-pituitary adrenal axis by activating 5-HT1A receptors, although activation of dopamine D2 receptors may contribute to these responses. Like other 5-HT1A receptor agonists, S-20499 does not increase renin secretion. Additionally, it reduces prolactin secretion, presumably by acting as a weak dopamine D2 receptor agonist in the pituitary.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalEuropean Journal of Pharmacology
Volume274
Issue number1-3
DOIs
StatePublished - Feb 14 1995
Externally publishedYes

Fingerprint

alnespirone
Anti-Anxiety Agents
Pharmaceutical Preparations
Adrenocorticotropic Hormone
Serotonin 5-HT1 Receptor Agonists
Receptor, Serotonin, 5-HT1A
Dopamine D2 Receptors
Corticosterone
Renin
Prolactin
Chromans
Pindolol
Spiperone
Dopamine Agonists
Heart Rate

Keywords

  • 5-HT (5-hydroxytryptamine, serotonin)
  • ACTH (adrenocorticotropin)
  • Blood pressure
  • Corticosterone
  • Heart rate
  • Prolactin
  • Renin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Neuroendocrine profile of the potential anxiolytic drug S-20499. / Levy, Andrew D.; Li, Qian; Gustafson, Michael; Van de Kar, Louis D.

In: European Journal of Pharmacology, Vol. 274, No. 1-3, 14.02.1995, p. 141-149.

Research output: Contribution to journalArticle

Levy, Andrew D. ; Li, Qian ; Gustafson, Michael ; Van de Kar, Louis D. / Neuroendocrine profile of the potential anxiolytic drug S-20499. In: European Journal of Pharmacology. 1995 ; Vol. 274, No. 1-3. pp. 141-149.
@article{994e805edd0a4781ba7e28330656463c,
title = "Neuroendocrine profile of the potential anxiolytic drug S-20499",
abstract = "The neuroendocrine profile of the serotonin 5-HT1A receptor agonist and potential anxiolytic drug (+)-4[N-(5-methoxy-chroman-3-yl]N-propylamino]butyl-8-azaspiro-(4, 5)-decane-7,9-dione (S-20499) was examined in conscious male rats. S-20499 (0.01-20 mg/kg i.p.) dose-dependently elevated plasma adrenocorticotropin (ACTH) and corticosterone concentrations, with maximal effects observed at 15-30 and 30-60 min respectively. S-20499 also reduced plasma prolactin concentration, and did not alter plasma renin activity. S-20499 (1 mg/kg i.p.) also reduced blood pressure and heart rate within 10 min, suggesting reduced sympathetic output. Pretreatment with the 5-HT1A0 receptor antagonists (-)-pindolol (0.3 mg/kg i.p.) or spiperone (0.01 or 3 mg/kg s.c.) significantly attenuated the stimulatory effects of S-20499 on plasma ACTH and/or corticosterone concentrations. The data suggest that S-20499 stimulates the hypothalamic-pituitary adrenal axis by activating 5-HT1A receptors, although activation of dopamine D2 receptors may contribute to these responses. Like other 5-HT1A receptor agonists, S-20499 does not increase renin secretion. Additionally, it reduces prolactin secretion, presumably by acting as a weak dopamine D2 receptor agonist in the pituitary.",
keywords = "5-HT (5-hydroxytryptamine, serotonin), ACTH (adrenocorticotropin), Blood pressure, Corticosterone, Heart rate, Prolactin, Renin",
author = "Levy, {Andrew D.} and Qian Li and Michael Gustafson and {Van de Kar}, {Louis D.}",
year = "1995",
month = "2",
day = "14",
doi = "10.1016/0014-2999(94)00719-N",
language = "English (US)",
volume = "274",
pages = "141--149",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Neuroendocrine profile of the potential anxiolytic drug S-20499

AU - Levy, Andrew D.

AU - Li, Qian

AU - Gustafson, Michael

AU - Van de Kar, Louis D.

PY - 1995/2/14

Y1 - 1995/2/14

N2 - The neuroendocrine profile of the serotonin 5-HT1A receptor agonist and potential anxiolytic drug (+)-4[N-(5-methoxy-chroman-3-yl]N-propylamino]butyl-8-azaspiro-(4, 5)-decane-7,9-dione (S-20499) was examined in conscious male rats. S-20499 (0.01-20 mg/kg i.p.) dose-dependently elevated plasma adrenocorticotropin (ACTH) and corticosterone concentrations, with maximal effects observed at 15-30 and 30-60 min respectively. S-20499 also reduced plasma prolactin concentration, and did not alter plasma renin activity. S-20499 (1 mg/kg i.p.) also reduced blood pressure and heart rate within 10 min, suggesting reduced sympathetic output. Pretreatment with the 5-HT1A0 receptor antagonists (-)-pindolol (0.3 mg/kg i.p.) or spiperone (0.01 or 3 mg/kg s.c.) significantly attenuated the stimulatory effects of S-20499 on plasma ACTH and/or corticosterone concentrations. The data suggest that S-20499 stimulates the hypothalamic-pituitary adrenal axis by activating 5-HT1A receptors, although activation of dopamine D2 receptors may contribute to these responses. Like other 5-HT1A receptor agonists, S-20499 does not increase renin secretion. Additionally, it reduces prolactin secretion, presumably by acting as a weak dopamine D2 receptor agonist in the pituitary.

AB - The neuroendocrine profile of the serotonin 5-HT1A receptor agonist and potential anxiolytic drug (+)-4[N-(5-methoxy-chroman-3-yl]N-propylamino]butyl-8-azaspiro-(4, 5)-decane-7,9-dione (S-20499) was examined in conscious male rats. S-20499 (0.01-20 mg/kg i.p.) dose-dependently elevated plasma adrenocorticotropin (ACTH) and corticosterone concentrations, with maximal effects observed at 15-30 and 30-60 min respectively. S-20499 also reduced plasma prolactin concentration, and did not alter plasma renin activity. S-20499 (1 mg/kg i.p.) also reduced blood pressure and heart rate within 10 min, suggesting reduced sympathetic output. Pretreatment with the 5-HT1A0 receptor antagonists (-)-pindolol (0.3 mg/kg i.p.) or spiperone (0.01 or 3 mg/kg s.c.) significantly attenuated the stimulatory effects of S-20499 on plasma ACTH and/or corticosterone concentrations. The data suggest that S-20499 stimulates the hypothalamic-pituitary adrenal axis by activating 5-HT1A receptors, although activation of dopamine D2 receptors may contribute to these responses. Like other 5-HT1A receptor agonists, S-20499 does not increase renin secretion. Additionally, it reduces prolactin secretion, presumably by acting as a weak dopamine D2 receptor agonist in the pituitary.

KW - 5-HT (5-hydroxytryptamine, serotonin)

KW - ACTH (adrenocorticotropin)

KW - Blood pressure

KW - Corticosterone

KW - Heart rate

KW - Prolactin

KW - Renin

UR - http://www.scopus.com/inward/record.url?scp=0028942095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028942095&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(94)00719-N

DO - 10.1016/0014-2999(94)00719-N

M3 - Article

C2 - 7768266

AN - SCOPUS:0028942095

VL - 274

SP - 141

EP - 149

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -